Registry of Dupuytren's Contracture Treatment Outcomes (ReDuCTO)

Technische Universität Dresden

Status

Completed

Conditions

Dupuytren's Disease

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT01567397

ReDuCTO ID 7090

Details and patient eligibility

About

Experience with Microbial Collagenase (trade name Xiapex) in Europe currently is limited to randomised controlled studies.While such studies are essential to determine efficacy and safety of the product (usually compared to placebo), they provide no information on the effectiveness of the drug and further aspects of its use (feasibility, tolerability, quality of life and other patient-related outcomes) in the typical "real-life" setting under clinical practice conditions.Thus, the present study aims to collect data on the

Drug utilization of Microbial Collagenase in the hand of physicians, with focus on feasibility, treatment patterns, and effectiveness in clinical practice
Context of Microbial Collagenase therapy (setting, patient characteristics, concomitant treatment, follow-up therapy)
Effectiveness (with focus on functionality)
Tolerability
Patient-related outcomes: patient satisfaction, health-related quality of life
Physician satisfaction with therapy
Resource utilization (hospital stays, drug consumption, concomitant medication etc.)
Long-term outcomes